PUT - SPRINTER OPEN END - ROCHE GS Share Price

Certificat

DE000VX9W473

Delayed Deutsche Boerse AG 13:02:08 10/05/2024 BST
19.53 EUR -1.41% Intraday chart for PUT - SPRINTER OPEN END - ROCHE GS
Current month-0.20%
1 month-1.00%
Date Price Change Volume
10/05/24 19.53 -1.41% 0
08/05/24 19.81 -0.40% 0
07/05/24 19.89 -1.34% 0
06/05/24 20.16 -0.84% 0
03/05/24 20.33 -1.45% 0

Delayed Quote Deutsche Boerse AG

Last update May 10, 2024 at 01:02 pm

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VX9W47
ISINDE000VX9W473
Date issued 07/04/2022
Strike 416.1 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 6.63
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 21.73
Lowest since issue 5.71
Spread 0.01
Spread %0.05%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
222.3 CHF
Average target price
279.4 CHF
Spread / Average Target
+25.68%
Consensus